annual EBITDA:
-$13.99M+$9.74M(+41.04%)Summary
- As of today (June 24, 2025), XERS annual EBITDA is -$13.99 million, with the most recent change of +$9.74 million (+41.04%) on December 31, 2024.
- During the last 3 years, XERS annual EBITDA has risen by +$99.67 million (+87.69%).
- XERS annual EBITDA is now -6.90% below its all-time high of -$13.09 million, reached on December 31, 2016.
Performance
XERS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
$1.23M-$4.50M(-78.54%)Summary
- As of today (June 24, 2025), XERS quarterly EBITDA is $1.23 million, with the most recent change of -$4.50 million (-78.54%) on March 1, 2025.
- Over the past year, XERS quarterly EBITDA has increased by +$9.65 million (+114.57%).
- XERS quarterly EBITDA is now -78.54% below its all-time high of $5.72 million, reached on December 31, 2024.
Performance
XERS quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$4.34M+$9.65M(+68.99%)Summary
- As of today (June 24, 2025), XERS TTM EBITDA is -$4.34 million, with the most recent change of +$9.65 million (+68.99%) on March 1, 2025.
- Over the past year, XERS TTM EBITDA has increased by +$20.39 million (+82.45%).
- XERS TTM EBITDA is now at all-time high.
Performance
XERS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
XERS EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +41.0% | +114.6% | +82.5% |
| 3 y3 years | +87.7% | +104.5% | +96.5% |
| 5 y5 years | +88.1% | +104.5% | +96.4% |
XERS EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +87.7% | -78.5% | +104.5% | at high | +96.5% |
| 5 y | 5-year | at high | +88.1% | -78.5% | +102.5% | at high | +96.5% |
| alltime | all time | -6.9% | +88.1% | -78.5% | +102.5% | at high | +96.5% |
XERS EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $1.23M(-78.5%) | -$4.34M(-69.0%) |
| Dec 2024 | -$13.99M(-41.0%) | $5.72M(-170.2%) | -$13.99M(-39.3%) |
| Sep 2024 | - | -$8.15M(+159.8%) | -$23.07M(+33.8%) |
| Jun 2024 | - | -$3.14M(-62.8%) | -$17.24M(-30.3%) |
| Mar 2024 | - | -$8.43M(+151.6%) | -$24.73M(+4.2%) |
| Dec 2023 | -$23.73M(-65.8%) | -$3.35M(+44.2%) | -$23.73M(-7.9%) |
| Sep 2023 | - | -$2.32M(-78.1%) | -$25.78M(-33.2%) |
| Jun 2023 | - | -$10.63M(+42.9%) | -$38.57M(-19.6%) |
| Mar 2023 | - | -$7.44M(+37.8%) | -$47.96M(-29.6%) |
| Dec 2022 | -$69.31M(-39.0%) | -$5.40M(-64.3%) | -$68.09M(-38.5%) |
| Sep 2022 | - | -$15.11M(-24.5%) | -$110.79M(-7.3%) |
| Jun 2022 | - | -$20.01M(-27.4%) | -$119.57M(-4.3%) |
| Mar 2022 | - | -$27.57M(-42.7%) | -$124.95M(+9.9%) |
| Dec 2021 | -$113.67M(+43.7%) | -$48.09M(+101.3%) | -$113.67M(+38.0%) |
| Sep 2021 | - | -$23.89M(-6.0%) | -$82.39M(+14.8%) |
| Jun 2021 | - | -$25.40M(+56.0%) | -$71.79M(+5.5%) |
| Mar 2021 | - | -$16.28M(-3.2%) | -$68.04M(-14.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | -$79.12M(-32.8%) | -$16.82M(+26.6%) | -$79.12M(-15.8%) |
| Sep 2020 | - | -$13.29M(-38.6%) | -$93.93M(-14.3%) |
| Jun 2020 | - | -$21.65M(-20.9%) | -$109.63M(-9.5%) |
| Mar 2020 | - | -$27.36M(-13.5%) | -$121.08M(+2.8%) |
| Dec 2019 | -$117.80M(+105.9%) | -$31.63M(+9.1%) | -$117.80M(+11.8%) |
| Sep 2019 | - | -$28.99M(-12.4%) | -$105.36M(+16.6%) |
| Jun 2019 | - | -$33.10M(+37.5%) | -$90.39M(+29.8%) |
| Mar 2019 | - | -$24.08M(+25.5%) | -$69.64M(+21.7%) |
| Dec 2018 | -$57.22M(+117.3%) | -$19.19M(+36.8%) | -$57.22M(+21.6%) |
| Sep 2018 | - | -$14.03M(+13.6%) | -$47.07M(+16.2%) |
| Jun 2018 | - | -$12.35M(+6.0%) | -$40.52M(+21.4%) |
| Mar 2018 | - | -$11.65M(+28.9%) | -$33.37M(+26.7%) |
| Dec 2017 | -$26.33M(+101.1%) | -$9.04M(+21.0%) | -$26.33M(+52.3%) |
| Sep 2017 | - | -$7.47M(+43.8%) | -$17.28M(+76.2%) |
| Jun 2017 | - | -$5.20M(+12.7%) | -$9.81M(+112.7%) |
| Mar 2017 | - | -$4.61M | -$4.61M |
| Dec 2016 | -$13.09M | - | - |
FAQ
- What is Xeris Biopharma Holdings annual EBITDA?
- What is the all time high annual EBITDA for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings annual EBITDA year-on-year change?
- What is Xeris Biopharma Holdings quarterly EBITDA?
- What is the all time high quarterly EBITDA for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings quarterly EBITDA year-on-year change?
- What is Xeris Biopharma Holdings TTM EBITDA?
- What is the all time high TTM EBITDA for Xeris Biopharma Holdings?
- What is Xeris Biopharma Holdings TTM EBITDA year-on-year change?
What is Xeris Biopharma Holdings annual EBITDA?
The current annual EBITDA of XERS is -$13.99M
What is the all time high annual EBITDA for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high annual EBITDA is -$13.09M
What is Xeris Biopharma Holdings annual EBITDA year-on-year change?
Over the past year, XERS annual EBITDA has changed by +$9.74M (+41.04%)
What is Xeris Biopharma Holdings quarterly EBITDA?
The current quarterly EBITDA of XERS is $1.23M
What is the all time high quarterly EBITDA for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high quarterly EBITDA is $5.72M
What is Xeris Biopharma Holdings quarterly EBITDA year-on-year change?
Over the past year, XERS quarterly EBITDA has changed by +$9.65M (+114.57%)
What is Xeris Biopharma Holdings TTM EBITDA?
The current TTM EBITDA of XERS is -$4.34M
What is the all time high TTM EBITDA for Xeris Biopharma Holdings?
Xeris Biopharma Holdings all-time high TTM EBITDA is -$4.34M
What is Xeris Biopharma Holdings TTM EBITDA year-on-year change?
Over the past year, XERS TTM EBITDA has changed by +$20.39M (+82.45%)